Cancer advocacy group lashes out at NICE's Lynparza No; Actavis closes on Auden Mckenzie deal;

@FiercePharma: ICYMI: Adding Opdivo to Yervoy ups melanoma treatment efficacy--but it ups rate of serious side effects, too. Report | Follow @FiercePharma

@CarlyHFierce: UPDATED w/Genentech comment: Roche's Gazyva doubles remission time for non-Hodgkin lymphoma patients. Story | Follow @CarlyHFierce

> No sooner had England's cost-effectiveness watchdogs issued a preliminary rejection to AstraZeneca's ($AZN) ovarian cancer drug Lynparza than Cancer Research UK stepped up to criticize it. Report

> Actavis ($ACT) wrapped up its £306 million buyout of niche U.K. drugmaker Auden Mckenzie. Release

> The health insurer Anthem ($WLP) says its new method for reimbursing cancer treatment has helped push doctors to use recommended regimens. Report

> India's retail drug-sellers plan a nationwide campaign against online medication sales. Report

> Foster Farms says it plans to mostly eliminate antibiotics used to treat human illnesses in its poultry. Report

> Teva Pharmaceutical ($TEVA) rolled out its generic version of Actonel, the osteoporosis med, and has 180-day exclusivity on the copy. Report

Medical Device News

@FierceMedDev: ICYMI: DOJ slaps Olympus with a subpoena over dirty duodenoscopes. Article | Follow @FierceMedDev

@VarunSaxena2: FMD exclusive (got insider tip): Zimmer to cut some staff as it barrels toward merger with Biomet. Story | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FiercePharma: Otsuka faces the music for generic Abilify, loses battle with FDA. Article | Follow @EmilyWFierce

> Molecular Dx: Invitae drops prices as NIH starts 1,000-patient, molecular abnormalities cancer study. More

> Startup Arsenal Medical and its spinoff raise $26.5M to develop novel foam, nanofiber and bioresorbable products. Article

Biotech News

@FierceBiotech: ASCO 15: The top 10 setbacks, advances and head scratchers. Editor's corner | Follow @FierceBiotech

@JohnCFierce: $IMGN shares up 14% on positive early data for ovarian cancer ADC. Release | Follow @JohnCFierce

> Bristol-Myers barrels toward approval with a blockbuster cancer combo. More

> Juno amps up its CAR-T tech in drive toward a pivotal test. Report

> Bristol-Myers fires off a lawsuit to sideline R&D defector headed to rival AstraZeneca. Story

> Alzheimer's biotech eyes $300M in a scaled-up IPO. Article

Animal Health News

> Tech makers market health wearables to dog owners. Item

> Groundbreaking held for the new $1.2B NABF animal health facility in Kansas. More

> Bayer CEO Dekkers looking 'with interest' at animal-health additions. Report

> K-State researchers build avian-flu protection into existing poultry vaccine. Article

> Novozymes enters booming market for poultry probiotics. Story

Biotech IT News

> CRISPR Therapeutics starts search for a bioinformatics chief. More

> Bioinformatics leads UCSD team to ovarian cancer biomarkers. Story

> AstraZeneca's Definiens rolls out biomarker data service. Item

> Artificial intelligence tops Google VC's list of high-potential life sci techs. Article

> UT Southwestern snags $5.6M grant to boost bioinformatics operation. Report

Pharma Marketing News

> Stars of cancer meeting set to crack top 10 cancer sales by 2020. Article

> Valeant plots big DTC push for Xifaxan while rival Actavis drug waits on DEA. Report

> Novartis rolls out 'life hacks' for MS patients with new Live Like You campaign. Article

> ASCO must-reads: Pfizer's Ibrance; BMS, Novartis melanoma meds; J&J's Imbruvica and more. More

> Abbott takes Pedialyte on the festival circuit as grown-up hangover remedy. Story

And Finally... The high-protein versus low-fat debate plays out in Dean Ornish scuffle in Scientific American. Report

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.